These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27648663)

  • 1. Compliance to vaginal treatment-tablets versus cream: a retrospective 9 years study.
    Weissmann-Brenner A; Bayevsky T; Yoles I
    Menopause; 2017 Jan; 24(1):73-76. PubMed ID: 27648663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice.
    Shulman LP; Portman DJ; Lee WC; Balu S; Joshi AV; Cobden D; Wang Q; Pashos CL
    J Womens Health (Larchmt); 2008 May; 17(4):569-78. PubMed ID: 18429700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
    Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
    Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.
    Portman D; Shulman L; Yeaw J; Zeng S; Uzoigwe C; Maamari R; Iyer NN
    Menopause; 2015 Nov; 22(11):1197-203. PubMed ID: 25944522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
    Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
    Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
    Crandall C
    J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
    Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
    Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream.
    Bhamra RK; Margolis MB; Liu JH; Hendy CH; Jenkins RG; DiLiberti CE
    Menopause; 2011 Apr; 18(4):393-9. PubMed ID: 21107298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
    Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
    Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of a plant-based, multi-component cream (Ginetrox®) in vulvovaginal disorders of the genitourinary syndrome during menopause.
    Marrai R; Lissi G; Togni S; Maramaldi G; Barbara M; Giacomelli L
    Minerva Ginecol; 2017 Jun; 69(3):245-249. PubMed ID: 28420227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women.
    Suwanvesh N; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Menopause; 2017 Feb; 24(2):210-215. PubMed ID: 27749740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aloe Vera; A new treatment for atrophic vaginitis, A randomized double-blinded controlled trial.
    Poordast T; Ghaedian L; Ghaedian L; Najib FS; Alipour S; Hosseinzadeh M; Vardanjani HM; Salehi A; Hosseinimehr SJ
    J Ethnopharmacol; 2021 Apr; 270():113760. PubMed ID: 33383112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
    Biglia N; Peano E; Sgandurra P; Moggio G; Panuccio E; Migliardi M; Ravarino N; Ponzone R; Sismondi P
    Gynecol Endocrinol; 2010 Jun; 26(6):404-12. PubMed ID: 20196634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.
    Dorr MB; Nelson AL; Mayer PR; Ranganath RP; Norris PM; Helzner EC; Preston RA
    Fertil Steril; 2010 Nov; 94(6):2365-8. PubMed ID: 20466363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience].
    Oliva FA; Saltarelli E; D'Antonio GD; Mazzatenta E
    Minerva Ginecol; 1991 Dec; 43(12):605-7. PubMed ID: 1819780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.